There were no statistical differences among the three groups in terms of age, tumor stage, routine pathological grading, tumor immunohistochemical status (ER, PR, Her-2, Ki67 index), tumor location, total hospitalization costs, or the proportion of patients receiving neoadjuvant therapy (Tables 1, 2). This evidence concerns the gene ERBB2 and neoplasm.